Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 16/20 | 0.67 |
| ▸ | TACR3 | P29371 | 16/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.67 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.53 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6857830 | 0.89 | TACR2 (0.55) | TACR2TACR3OPRM1TRPV4DHODH | |
| SCHEMBL6852921 | 0.87 | TACR2 (0.53) | TACR2TACR3OPRM1TRPV4DHODH | |
| Hydrochloric Acid SCHEMBL6851636 | 0.86 | TACR3 (0.52) | TACR2TACR3OPRM1TRPV4KCNH2 | |
| SCHEMBL6202262 | 0.85 | TACR2 (0.51) | TACR2TACR3OPRM1TRPV4DHODH | |
| SCHEMBL6200694 | 0.85 | TACR2 (0.51) | TACR2TACR3OPRM1TRPV4DHODH | |
| SCHEMBL6200702 | 0.85 | TACR2 (0.51) | TACR2TACR3OPRM1TRPV4DHODH | |
| SCHEMBL2373330 | 0.84 | TRPV4 (0.72) | TACR2TACR3OPRM1TRPV4KCNH2 | |
| SCHEMBL6853012 | 0.84 | TACR3 (0.64) | TACR2TACR3OPRM1DHODHPDE10A | |
| SCHEMBL5908826 | 0.84 | TACR2 (0.56) | TACR2TACR3OPRM1DHODHPDE10A | |
| Hydrochloric Acid SCHEMBL5733490 | 0.84 | TRPV4 (0.71) | TACR2TACR3OPRM1TRPV4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6780875-B2 | RESPIRATORY SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS; PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-08-24 | — | — | US | claimed |
| US-20060161004-A1 | Novel compounds | GLAXOSMITHKLINE SPA | 2006-07-20 | — | — | US | disclosed |
| US-20050070574-A1 | Novel compounds | GLAXOSMITHKLINE SPA AND LABORATOIRE | 2005-03-31 | — | — | US | disclosed |
| US-6780875-B2 | RESPIRATORY SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS; PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-08-24 | — | — | US | disclosed |
| US-20040102633-A1 | Novel compounds | GLAXOSMITHKLINE S.P.A. (IT) | 2004-05-27 | — | — | US | disclosed |
| US-20030212101-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | SMITHKLINE BEECHAM S.P.A. (IT) | 2003-11-13 | — | — | US | disclosed |
| EP-1339691-A1 | NOVEL COMPOUNDS | GlaxoSmithKline S.p.A. (IT) | 2003-09-03 | — | — | EP | disclosed |
| CN-1407850-A | Process for converting storage reserves of dicot seeds into compositions comprising one or more gene products | UNICROP LTD (FI) | 2003-04-02 | — | — | CN | disclosed |
| CN-1406225-A | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | GLAXO SMITHKLINE S P A (IT) | 2003-03-26 | — | — | CN | disclosed |
| WO-2002044154-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE SPA (IT) | 2002-06-06 | — | — | WO | disclosed |
| EP-1131295-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | Smithkline Beecham S.p.A. (IT) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000031037-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM S.P.A. (IT) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070574-A1 | Novel compounds | NR1H3, NR1H2, CNR1 | TACR2 52/4885TACR3 301/4885OPRM1 40/4885 |
| US-20030212101-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | KCNH2, KCNA6, KCNA3 | TACR2 21/4885TACR3 86/4885OPRM1 228/4885 |
| US-20060161004-A1 | Novel compounds | SLC10A1, ABCB11, AQP1 | TACR2 862/4885TACR3 2824/4885OPRM1 2549/4885 |
| US-20040102633-A1 | Novel compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, NR1H3 | TACR2 155/4885TACR3 1027/4885OPRM1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.